Literature DB >> 21482679

Erlotinib-mediated inhibition of EGFR signaling induces metabolic oxidative stress through NOX4.

Kevin P Orcutt1, Arlene D Parsons, Zita A Sibenaller, Peter M Scarbrough, Yueming Zhu, Arya Sobhakumari, Werner W Wilke, Amanda L Kalen, Prabhat Goswami, Francis J Miller, Douglas R Spitz, Andrean L Simons.   

Abstract

Redox regulation of epidermal growth factor receptor (EGFR) signaling helps protect cells against oxidative stress. In this study, we investigated whether the cytotoxicity of an EGFR tyrosine kinase inhibitor, erlotinib (ERL), was mediated by induction of oxidative stress in human head and neck cancer (HNSCC) cells. ERL elicited cytotoxicity in vitro and in vivo while increasing a panel of oxidative stress parameters which were all reversible by the antioxidant N-acetyl cysteine. Knockdown of EGFR by using siRNA similarly increased these oxidative stress parameters. Overexpression of mitochondrial targeted catalase but not superoxide dismutase reversed ERL-induced cytotoxicity. Consistent with a general role for NADPH oxidase (NOX) enzymes in ERL-induced oxidative stress, ERL-induced cytotoxicity was reversed by diphenylene iodonium, a NOX complex inhibitor. ERL reduced the expression of NOX1, NOX2, and NOX5 but induced the expression of NOX4. Knockdown of NOX4 by using siRNA protected HNSCC cells from ERL-induced cytotoxicity and oxidative stress. Our findings support the concept that ERL-induced cytotoxicity is based on a specific mechanism of oxidative stress mediated by hydrogen peroxide production through NOX4 signaling.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21482679      PMCID: PMC3217301          DOI: 10.1158/0008-5472.CAN-10-3425

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

Review 1.  The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification.

Authors:  N Prenzel; O M Fischer; S Streit; S Hart; A Ullrich
Journal:  Endocr Relat Cancer       Date:  2001-03       Impact factor: 5.678

2.  Epidermal growth factor receptor-dependent Akt activation by oxidative stress enhances cell survival.

Authors:  X Wang; K D McCullough; T F Franke; N J Holbrook
Journal:  J Biol Chem       Date:  2000-05-12       Impact factor: 5.157

3.  Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.

Authors:  John C Sok; Francesca M Coppelli; Sufi M Thomas; Miriam N Lango; Sichuan Xi; Jennifer L Hunt; Maria L Freilino; Michael W Graner; Carol J Wikstrand; Darell D Bigner; William E Gooding; Frank B Furnari; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2006-09-01       Impact factor: 12.531

4.  UVB-induced epidermal growth factor receptor phosphorylation is critical for downstream signaling and keratinocyte survival.

Authors:  D Peus; R A Vasa; A Meves; A Beyerle; M R Pittelkow
Journal:  Photochem Photobiol       Date:  2000-07       Impact factor: 3.421

5.  Production of large amounts of hydrogen peroxide by human tumor cells.

Authors:  T P Szatrowski; C F Nathan
Journal:  Cancer Res       Date:  1991-02-01       Impact factor: 12.701

Review 6.  Reactive oxygen species-dependent signaling regulates cancer.

Authors:  Frank Weinberg; Navdeep S Chandel
Journal:  Cell Mol Life Sci       Date:  2009-07-24       Impact factor: 9.261

7.  Cell division in normal and transformed cells: the possible role of superoxide and hydrogen peroxide.

Authors:  L W Oberley; T D Oberley; G R Buettner
Journal:  Med Hypotheses       Date:  1981-01       Impact factor: 1.538

8.  Distinct roles of Nox1 and Nox4 in basal and angiotensin II-stimulated superoxide and hydrogen peroxide production.

Authors:  Sergey I Dikalov; Anna E Dikalova; Alfiya T Bikineyeva; Harald H H W Schmidt; David G Harrison; Kathy K Griendling
Journal:  Free Radic Biol Med       Date:  2008-08-16       Impact factor: 7.376

9.  Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines.

Authors:  Yi-He Ling; Tianhong Li; Ziqiang Yuan; Missak Haigentz; Thomas K Weber; Roman Perez-Soler
Journal:  Mol Pharmacol       Date:  2007-04-24       Impact factor: 4.436

Review 10.  EGFR targeting of solid tumors.

Authors:  Caio M Rocha-Lima; Heloisa P Soares; Luis E Raez; Rakesh Singal
Journal:  Cancer Control       Date:  2007-07       Impact factor: 3.302

View more
  38 in total

Review 1.  Autophagic action of new targeting agents in head and neck oncology.

Authors:  Hidemi Rikiishi
Journal:  Cancer Biol Ther       Date:  2012-07-24       Impact factor: 4.742

2.  Chemical methods for the simultaneous quantitation of metabolites and proteins from single cells.

Authors:  Min Xue; Wei Wei; Yapeng Su; Jungwoo Kim; Young Shik Shin; Wilson X Mai; David A Nathanson; James R Heath
Journal:  J Am Chem Soc       Date:  2015-03-19       Impact factor: 15.419

3.  EGFR-TKI, erlotinib, causes hypomagnesemia, oxidative stress, and cardiac dysfunction: attenuation by NK-1 receptor blockade.

Authors:  I Tong Mak; Jay H Kramer; Joanna J Chmielinska; Christopher F Spurney; William B Weglicki
Journal:  J Cardiovasc Pharmacol       Date:  2015-01       Impact factor: 3.105

4.  Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM.

Authors:  Andrew McKinney; Olle R Lindberg; Jane R Engler; Katharine Y Chen; Anupam Kumar; Henry Gong; Kan V Lu; Erin F Simonds; Timothy F Cloughesy; Linda M Liau; Michael Prados; Andrew W Bollen; Mitchel S Berger; Joseph T C Shieh; C David James; Theodore P Nicolaides; William H Yong; Albert Lai; Monika E Hegi; William A Weiss; Joanna J Phillips
Journal:  Mol Cancer Ther       Date:  2019-07-03       Impact factor: 6.261

5.  MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.

Authors:  Adam T Koch; Laurie Love-Homan; Madelyn Espinosa-Cotton; Aditya Stanam; Andrean L Simons
Journal:  Cancer Res       Date:  2015-02-20       Impact factor: 12.701

6.  EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC.

Authors:  Elise V M Fletcher; Laurie Love-Homan; Arya Sobhakumari; Charlotte R Feddersen; Adam T Koch; Apollina Goel; Andrean L Simons
Journal:  Mol Cancer Res       Date:  2013-09-18       Impact factor: 5.852

7.  Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.

Authors:  Barbara A Frederick; Rohit Gupta; Amandla Atilano-Roque; Tin Tin Su; David Raben
Journal:  Radiat Res       Date:  2020-11-10       Impact factor: 2.841

8.  NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells.

Authors:  Arya Sobhakumari; Brandon M Schickling; Laurie Love-Homan; Ayanna Raeburn; Elise V M Fletcher; Adam J Case; Frederick E Domann; Francis J Miller; Andrean L Simons
Journal:  Toxicol Appl Pharmacol       Date:  2013-07-31       Impact factor: 4.219

Review 9.  Targeting NADPH oxidases for the treatment of cancer and inflammation.

Authors:  Michael Y Bonner; Jack L Arbiser
Journal:  Cell Mol Life Sci       Date:  2012-05-13       Impact factor: 9.261

10.  EGFR tyrosine kinase inhibition induces autophagy in cancer cells.

Authors:  Christopher Fung; Xing Chen; Jennifer R Grandis; Umamaheswar Duvvuri
Journal:  Cancer Biol Ther       Date:  2012-09-06       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.